from Econsalut at http://bit.ly/33fpoGR on November 22, 2019 at 07:33AM El enemigo conoce el sistema Manipulación de ideas, personas e influencias después de la economía de la atención Uno de los errores recurrentes de la izquierda es pensar que el populismo es la… [[ This is a content summary only. Visit my website for full […]
from Applied Health Economics and Health Policy at http://bit.ly/2OxSfR7 on November 22, 2019 at 03:16AM Abstract Background Influenza is an infectious disease causing a high annual economic and public health burden. The most efficient management of the disease is through prevention with vaccination. Many influenza vaccines are available, with varying efficacy and cost, targeting different […]
from PharmacoEconomics at http://bit.ly/2rj7k0Q on November 22, 2019 at 02:21AM Abstract Background Clinical trials often report intervention efficacy in terms of the reduction in all-cause mortality between the treatment and control arms (i.e., an overall hazard ratio [oHR]) instead of the reduction in disease-specific mortality (i.e., a disease-specific hazard ratio [dsHR]). Using oHR to reduce […]
from Brookings: Topics – Health at https://brook.gs/2rirXu5 on November 21, 2019 at 10:51PM By Erin Trish, Paul Ginsburg, Geoffrey Joyce, Dana Goldman
from Brookings: Topics – Health at https://brook.gs/2rirXu5 on November 21, 2019 at 08:22PM By Erin Trish, Paul Ginsburg, Geoffrey Joyce, Dana Goldman
from RAND Research Topic: Health and Health Care at http://bit.ly/34beD9w on November 21, 2019 at 07:13PM Like many fields, health services research relies on peer review to assure rigor and relevance. However, evidence demonstrates that the current approach is time-consuming for both researchers and reviewers, has limited power to predict research outcomes, and is subject […]
from The European Journal of Health Economics at http://bit.ly/2raNogW on November 21, 2019 at 06:31PM Abstract In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive meningococcal disease (IMD). The panel discussed […]
